Affimed Presents Preclinical Data Showing That Addition Of An Innate Cell Engager To NK And CAR-NK Cells Improves Tumor Cytotoxicity Of Both Cell Types At The 38th Annual Meeting Of The Society For Immunotherapy Of Cancer
Portfolio Pulse from Benzinga Newsdesk
Affimed presented preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, showing that the addition of its innate cell engager (ICE) improves the cytotoxicity of natural killer (NK) and CAR-NK cells. The use of ICE with NK cells eliminates the need for complex and costly manufacturing compared to CAR-NK cells, and offers flexibility to be used with NK cells from different sources.
November 03, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Affimed's preclinical data shows that its innate cell engager (ICE) improves the cytotoxicity of NK and CAR-NK cells. This could potentially simplify the manufacturing process and offer flexibility in cell sourcing.
The news is directly related to Affimed's product, the innate cell engager (ICE), and its potential in improving the cytotoxicity of NK and CAR-NK cells. This could potentially simplify the manufacturing process and offer flexibility in cell sourcing, which could have a positive impact on the company's operations and financial performance. Therefore, the short-term impact on the company's stock price is likely to be positive.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100